Skip to main content
Client Work

Edesa Biotech, Inc. closes US$10 million bought deal offering of common shares

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

Edesa Biotech Inc.

On March 2, 2021 Edesa Biotech, Inc. closed a bought deal public offering of 1,562,500 of its common shares, at a price to the public of US$6.40 per share. The gross proceeds were US$10,000,000 before deducting underwriting commissions and discounts and other offering expenses payable by Edesa.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases.

Fasken acted as Canadian counsel to Edesa Biotech, Inc. with a team led by Wojtek Baraniak and including Myroslav Chwaluk, Samuel Li, Kevin Yip and Jordana Keslassy.

Jurisdiction

  • Ontario

Team

    Subscribe

    Receive email updates from our team

    Subscribe